HMG Stimulation Versus HRT for Endometrial Preparation Prior to Blastocyst Transfer in Moderate to Severe IUA Patients

NACompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

October 20, 2019

Study Completion Date

November 20, 2019

Conditions
Infertility, FemaleIntrauterine Adhesion
Interventions
DRUG

human menopausal gonadotrophin

experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)\<100pg/ml,progesterone (P)\<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.

DRUG

hormone replacement therapy

Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration \>60 days.

Trial Locations (1)

410000

Reproductive & Genetic Hospital of CITIC-XIANGYA, Changsha

All Listed Sponsors
lead

Reproductive & Genetic Hospital of CITIC-Xiangya

OTHER

NCT03578172 - HMG Stimulation Versus HRT for Endometrial Preparation Prior to Blastocyst Transfer in Moderate to Severe IUA Patients | Biotech Hunter | Biotech Hunter